We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

LumiQuick Diagnostics

LumiQuick Diagnostics Inc. develops, manufactures and markets high quality point of care tests and other immunoassay ... read more Featured Products: More products

Download Mobile App




Lumiquick Acquires Aoxre to Expand Global IVD and Research Capabilities

By LabMedica International staff writers
Posted on 29 Sep 2025

Oxidative stress has been linked to cellular damage involving proteins, DNA, and lipids, and it plays a role in conditions such as cardiovascular disorders, diabetes, neurodegenerative diseases (Alzheimer’s and Parkinson’s), cancer, and chronic infections. More...

Detecting and monitoring oxidative stress biomarkers is essential for both clinical diagnostics and research, yet current tools remain fragmented and limited in reach. To address this, a major acquisition is set to expand global access to advanced diagnostic solutions and research tools.

Lumiquick Diagnostics (Santa Clara, CA, USA), a developer and manufacturer of in vitro diagnostic (IVD) tests, has acquired AOXRE LLC (Burlingame, CA, USA), which is recognized for its innovative OxisResearch product line. At the heart of the OxisResearch product line are the Bioxytech assay kits targeting oxidative and nitrosative stress biomarkers.

With this acquisition, customers can expect the full product line of oxidative stress markers and companion diagnostic assays, including Cellular Damage Monitoring, REDOX balance assessment, ELISA, and rapid test of various biological markers that are associated with the oxidation status of the human body.

This strategic acquisition marks a significant milestone for Lumiquick as it continues to expand its global footprint and product portfolio in the IVD & research industries. AOXRE’s expertise, technology, and customer relationships will be fully integrated into Lumiquick’s operations, strengthening the company’s position as a comprehensive provider of high-quality diagnostic and research tools.

“We are thrilled to welcome AOXRE into the Lumiquick Diagnostics family,” said Charles Yu, President of Lumiquick Diagnostics. “The addition of the AOXRE product line will strengthen LumiQuick’s ability to support both the clinical and research communities.”

Related Links:
Lumiquick Diagnostics
AOXRE LLC


Gold Member
Automatic Hematology Analyzer
CF9600
Online QC Software
Acusera 24•7
Electrolyte Analyzer
BKE-B
Immunofluorescence Analyzer
IFA System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Capillary testing on the Atellica analyzers supports the most common laboratory testing needs (Photo courtesy of Siemens Healthineers)

Siemens Adds CE-Marked Capillary Claims for 24 Assays on Atellica Analyzers

Venous blood draws can be challenging in patients with difficult veins, needle phobia, or limited blood volume, and they can slow collection in busy services. Core laboratories also face pressure to expand... Read more

Immunology

view channel
Image: Graphical Abstract (Morgane Fournier et al., Cell (2026). DOI: 10.1016/j.cell.2026.04.013)

Study Reveals Immune Mechanism Driving Severe COVID-19 Progression

Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more

Pathology

view channel
Image: Agilent’s PD-L1 IHC 22C3 pharmDx has received EU certification as a companion diagnostic to identify PD-L1–positive ovarian, fallopian tube, or primary peritoneal carcinoma patients eligible for KEYTRUDA (Photo courtesy of Agilent)

PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers

Agilent Technologies’ PD-L1 IHC 22C3 pharmDx (Code SK006) has received European Union certification as a companion diagnostic to aid in identifying patients with epithelial ovarian, fallopian tube, or... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.